| Literature DB >> 30109767 |
Elisabetta Mattioli1,2, Davide Andrenacci1,2, Cecilia Garofalo2,3, Sabino Prencipe1,2, Katia Scotlandi2,3, Daniel Remondini4, Davide Gentilini5, Anna Maria Di Blasio5, Sergio Valente6, Emanuela Scarano7, Lucia Cicchilitti8, Giulia Piaggio8, Antonello Mai6, Giovanna Lattanzi1,2.
Abstract
Defects in stress response are main determinants of cellular senescence and organism aging. In fibroblasts from patients affected by Hutchinson-Gilford progeria, a severe LMNA-linked syndrome associated with bone resorption, cardiovascular disorders, and premature aging, we found altered modulation of CDKN1A, encoding p21, upon oxidative stress induction, and accumulation of senescence markers during stress recovery. In this context, we unraveled a dynamic interaction of lamin A/C with HDAC2, an histone deacetylase that regulates CDKN1A expression. In control skin fibroblasts, lamin A/C is part of a protein complex including HDAC2 and its histone substrates; protein interaction is reduced at the onset of DNA damage response and recovered after completion of DNA repair. This interplay parallels modulation of p21 expression and global histone acetylation, and it is disrupted by LMNAmutations leading to progeroid phenotypes. In fact, HGPS cells show impaired lamin A/C-HDAC2 interplay and accumulation of p21 upon stress recovery. Collectively, these results link altered physical interaction between lamin A/C and HDAC2 to cellular and organism aging. The lamin A/C-HDAC2 complex may be a novel therapeutic target to slow down progression of progeria symptoms.Entities:
Keywords: CDKN1A (p21WAF1/Cip1); Hutchinson-Gilford progeria syndrome (HGPS); aging; histone deacetylase 2 (HDAC2); lamin A/C; oxidative stress
Mesh:
Substances:
Year: 2018 PMID: 30109767 PMCID: PMC6156291 DOI: 10.1111/acel.12824
Source DB: PubMed Journal: Aging Cell ISSN: 1474-9718 Impact factor: 9.304
List of human dermal fibroblast cultures used in this study
| Fibroblasts culture |
| Age of donor at biopsy | Gender | Passage number | Used for |
|---|---|---|---|---|---|
| CONTROL 1 | None | 15 | F | 18–22 | MA,WB, IF, PLA |
| CONTROL 2 | None | 65 | M | 14–18 | MA, IF, PLA |
| APS (atypical progeria syndrome) | P4R | 17 | F | 14–15 | WB, PLA |
| MADA (Mandibuloacral dysplasia A type) | R527H | 50 | M | 13–14 | WB, PLA |
| HGPS (Hutchinson–Gilford progeria syndrome)1 | G608G | 6 | M | 20–24 | MA, WB, IF, PLA |
| HGPS (Hutchinson–Gilford progeria syndrome)2 | G608G | 3 | F | 12–14 | MA |
| EDMD2 (Emery‐Dreifuss muscular dystrophy) | Y259D | 11 | F | 14–16 | WB, PLA |
IF: immunofluorescence; MA: microarray; PLA: proximity ligation assay; WB: western blot analysis.
Figure 1Altered p21 modulation during stress response in HGPS cells. Control or HGPS fibroblasts were left untreated (NT), exposed to H2O2 for 4 hr (H2O2), or harvested after 48 hr of H2O2 recovery (recovery). (a) Sketch of the oxidative stress experiment aligned along the time axis. (b) Quantitative RT‐PCR of CDKN1A expression. (c) (i) Western blot of p53, phospho‐p53 (p53–S15), and p21; (ii) densitometry of p21 bands, (iii) densitometry of p53 bands, and (iv) densitometry of p53–S15 bands; (d) (i) SA‐βGal staining of control and HGPS cells left untreated or after H2O2 recovery; (ii) quantitative analysis of SA‐βGal‐positive cells. (e) SA‐βGal and DAPI co‐staining in normal and HGPS cells showing SAHF (arrowheads). (f) (i) DAPI staining of nuclei of normal, APS, MADA, and HGPS fibroblasts; (ii) percentage of cells with SAHF
Genes differently regulated upon stress in HGPS cells. Changes in gene expression in control and HGPS cells subjected to 4‐hr H2O2 treatment are reported. A ratio >1.8 or a ratio <0.55 in control or HGPS was used in the study
| Gene symbol | Change in control upon stress | Change in HGPS upon stress | Gene designation | Annotated functions |
|
|
|---|---|---|---|---|---|---|
|
| 76,1 |
| AP−1 transcription factor subunit | Involved in cell proliferation and differentiation | X | |
|
| 10,3 |
| Growth arrest and DNA damage‐inducible alpha | Involved in stress response | X | |
|
| 6,6 |
| Growth differentiation factor 15 | Involved in stress response | X | |
|
| 2,1 |
| SplA/ryanodine receptor domain | Probable substrate recognition component of a SCF‐like ECS | ||
|
| 2,8 |
| Ras‐related glycolysis inhibitor | Interacts with CAMK2G and TPM2 | X | |
|
| 2,5 |
| SERTA domain containing 1 | Interacts with p16, CREB‐binding protein, and CDK4 | ||
|
| 3,5 |
| T‐box3 | Regulator of developmental processes | ||
|
| 1,4 |
| Protein phosphatase 1 regulatory subunit 10 | Involved in cell cycle progression, DNA repair, and apoptosis | ||
|
| 1,7 |
| Chromobox homolog 4 | Epigenetic regulation of cell proliferation and differentiation | X | |
|
| 1,3 |
| MicroRNA320a | Regulator of gene expression | ||
|
| 2,0 |
| CCAAT/enhancer binding protein gamma | Regulator of viral and cellular transcription | X | |
|
| 1,1 |
| CCAAT/enhancer binding protein alpha | Involved in cell cycle progression | X | |
|
| 1,9 |
| Matrix metallopeptidase 25 | Involved in the breakdown of extracellular matrix | ||
|
| 2,3 |
| Nuclear receptor subfamily 4 group A member 2 | Regulator of gene expression | X | |
|
| 1,4 |
| Kruppel‐like factor 6 | Involved in the tumor suppression | X | |
|
| 1,54 |
| Lactate dehydrogenase C | Enzyme involved in anaerobic glycolysis | ||
|
| 1,1 |
| OTU deubiquitinase 1 | Deubiquitinating enzymes | ||
|
| 1,5 |
| Dual specificity phosphatase 16 | Gene expression, cell proliferation, differentiation, and apoptosis | ||
|
| 1,7 |
| Cysteine and serine‐rich nuclear protein 2 | Regulator of gene expression | ||
|
| 1,1 |
| Rho family GTPase 1 | Involved in the organization of the actin cytoskeleton | ||
|
|
| 2,0 | Cyclin‐dependent kinase inhibitor 1 | Cell cycle progression, DNA replication, and DNA damage repair | X | X |
|
| 0,7 |
| Disco‐interacting protein 2 homolog A | Involved in axon patterning in the central nervous system | ||
|
| 0,8 |
| Asteroid homolog 1 | Regulator of gene expression | ||
|
| 0,6 |
| AP2‐associated kinase 1 | Involved in endocytosis process |
*Statistically significant difference relative to corresponding untreated samples, p < 0.01.
**S, stress involvement.
gene is the only gene in the list involved in both stress and lamin A‐related mechanisms.
***L, lamin interplay.
Figure 2Regulation of stress response and p21 by lamin A/C. (a) String map (https://string-db.org/) indicating interconnections among genes analyzed in the microarray reported in Table 2. Genes upregulated in HGPS after H2O2 treatment with respect to H2O2‐treated human normal fibroblasts are indicated by an arrow, and genes whose regulation after H2O2 treatment is hampered in HGPS are indicated by the symbol ┤. (b) (i) Chromatin immunoprecipitation (ChIP) of lamin A/C on the CDKN1A promoter in normal fibroblasts. The promoter of CDKN1A and CXCR4 (unrelated promoter) was detected by qPCR with specific primers listed in Experimental procedures. Protein binding is expressed as the percentage of the total DNA input. CDKN1A promoter regions bound by lamin A/C (R1, R2, R3, R4) are indicated; (ii) Schematic representation of regions bound by lamin A/C (R1, R2, R3, R4), on CDKN1A gene promoter. (c) (i) Western blot of p21, lamin A/C and HDAC2 in fibroblasts left untreated or after siRNA silencing of HDAC2 or Lamin A/C and (ii) corresponding densitometry. (d) ChIP of (i) lamin A/C or (ii) HDAC2 on the CDKN1A promoter in normal or HGPS fibroblasts. CDKN1A promoter region (R4) bound by lamin A/C or HDAC2 is indicated
Figure 3Lamin A/C interacts with HDAC2 in human normal fibroblasts more strongly than progeroid mutants. (a) Co‐IP of GFP‐lamin A and FLAG‐HDAC2 (IP FLAG) in HEK293 cells. IP control IgG, negative control. Molecular weight markers are indicated. (b) (i) Immunofluorescence staining of lamin A/C and HDAC2 and PLA of lamin A/C and HDAC2 (PLA) in human normal fibroblasts. PLA of lamin A/C and HDAC2 and lamin A/C staining are merged in the right picture (merge); (ii) percentage of nuclei showing less than 50% of signals at the periphery (PLA lamin A/C‐HDAC2 homogenous distribution) or more than 50% of signals at the periphery (PLA lamin A/C‐HDAC2 enrichment at the periphery); (iii) fluorescence intensity profile of lamin A/C and HDAC2 in a representative nucleus. (c) (i) PLA of lamin A/C and HDAC2 in the presence (left picture) or absence of lamin A/C antibody (no anti‐lamin A/C antibody) and (ii) quantitative analysis; (iii) PLA of lamin A/C and HDAC2 after HDAC2 knockdown (HDAC2 siRNA); (iv) PLA of lamin A/C and HDAC2 after lamin A/C knockdown (lamin A/C siRNA) and (v) quantitative analysis of PLA signals in the indicated samples; (vi) lamin A/C and MEF2c staining and PLA of lamin A/C and MEF2c (no signals were detected). (d) (i) PLA of lamin A/C and HDAC2 in fibroblasts from healthy subjects, HGPS, APS, MADA, or EDMD2 patients (see Table 1 for details) and (ii) quantitative analysis of PLA. (e) (i) Selected focal planes from the z‐stack of nuclei from normal or HGPS cells subjected to lamin A/C‐HDAC2 PLA. PLA signals are red dots, IF staining of lamin A/C is shown in green; (ii) number of PLA signals at the nuclear periphery reported as percentage of total PLA signals. (f) (i) Co‐IP of lamin A/C and HDAC2 in normal or HGPS fibroblasts (IP lamin A/C) and (ii) densitometric analysis of immunoprecipitated HDAC2. (g) (i) Co‐IP of FLAG‐lamin A or FLAG‐progerin and endogenous HDAC2 in HEK293 cells. IP control IgG, negative control; (ii) quantitative analysis of immunoprecipitated HDAC2, values were normalized to immunoprecipitated LMNA products. (h) (i) PLA of progerin and HDAC2 in HGPS cells and quantitative analysis of PLA signals. (ii) PLA of lamin A/C and HDAC2 in control fibroblasts transfected with WT FLAG‐lamin A or FLAG‐progerin. FLAG staining (green) is merged with DAPI. p21 co‐staining is shown on the right (p21).Representative nuclei out of 100 examined nuclei are shown; (iii) quantitative analysis of PLA signals in transfected cells performed in nuclei showing the same fluorescence intensity values for FLAG; (iv) p21 mean fluorescence intensity in transfected cells. Nuclei in c, d, e, h were counterstained with DAPI
Figure 4Lamin A/C complexes with acetylated HDAC2 substrates and influences HDAC2 activity. (a) (i) Human normal (control) or HGPS fibroblasts (HGPS) subjected to IF for H4K16ac and HDAC2 and PLA for HDAC2‐H4K16ac interaction. Cells treated with MS275 (MS275) were used as controls; (ii) quantitative analysis of PLA signals; (iii) western blot analysis of H4K16ac in control and HGPS cells or in control cells treated with MS275; (iv) mean densitometric values of immunoblotted H4K16ac bands. (b) (i) IF analysis of H4K16ac and lamin A/C and PLA for H4K16ac‐lamin A/C interaction in normal and HGPS cells and (ii) quantitative analysis of PLA signals. (c) (i) IF analysis of H3K9ac and lamin A/C and PLA for lamin A/C‐H3K9ac interaction and (ii) quantitative analysis of PLA signals. (d) (i) IF analysis of lamin A/C and pHDAC2 and PLA for lamin A/C‐pHDAC2 interaction in normal and HGPS cells; (ii) quantitative analysis of PLA signals and (iii) percentage of signals at the periphery with respect to total signals; (iv) fluorescence intensity profile of lamin A/C and pHDAC2 in representative nuclei of control or HGPS cells. (e) (i) PLA of progerin and pHDAC2 in HGPS cells; (ii) quantitative analysis of lamin A/C‐pHDAC2 and progerin‐pHDAC2 PLA signals in HGPS cells. (f) (i) Co‐IP of GFP‐lamin A (IP GFP) and WT FLAG‐HDAC2, S392D FLAG‐HDAC2, or S394A FLAG‐HDAC2 in transfected HEK293 cells. IP control IgG, negative control; (ii) densitometry of immunoprecipitated protein bands. (g) (i) Western blot analysis of H4K16ac and H3K9ac in non‐transfected HEK293 cells or cells overexpressing HDAC2, lamin A/HDAC2, or progerin/HDAC2 as reported in the legend; (ii) densitometry of H3K9ac and (iii) H4K16ac immunoblotted bands normalized to H3 values. Nuclei in a, b, c, d, e were counterstained with DAPI
Figure 5Altered modulation of lamin A/C‐HDAC2 interaction during DDR in HGPS cells. Normal (control) or HGPS fibroblasts (HGPS) were left untreated (NT), exposed to H2O2 for 4 hr (H2O2), or harvested after 48 hr of H2O2 recovery (recovery). (a) (i) PLA of lamin A/C and HDAC2 in normal human fibroblasts and (ii) quantitative analysis of PLA signals; (iii) PLA of lamin A/C and HDAC2 in HGPS cells and (iv) quantitative analysis. 53BP1 foci in (i) and (iii) are markers of DNA damage. (b) (i) IF of HDAC2 (HDAC2) in control and HGPS cells during DDR; (ii) fluorescence intensity profile of HDAC2 during DDR measured in a representative control or (iii) HGPS nucleus. (c) (i) Western blot analysis of HDAC2 in control and HGPS cells during DDR; (ii) densitometry of immunoblotted HDAC2 bands. (d) (i) PLA of HDAC2 and H4K16ac in normal and HGPS cells during DDR and (ii) quantitative analysis of PLA signals. Nuclei are counterstained with DAPI. (e) (i) H3K9ac IF staining and (ii) quantitative analysis of mean fluorescence intensity during DDR in normal or HGPS cells. (f) (i) H4K16ac IF staining and (ii) quantitative analysis of mean fluorescence intensity during DDR in normal or HGPS cells
List of antibodies used in this study
| ANTIBODY | Code | Species | IF dilution | WB dilution | PLA dilution | ChIP | IP |
|---|---|---|---|---|---|---|---|
| anti‐lamin A/C | Santa Cruz, SC‐6215 ( | Goat polyclonal | 1:100 | 1:100 | 1:100 | 4 µg | |
| anti‐lamin A/C | Novocastra (C‐terminus) | Mouse monoclonal | 4 µg | ||||
| anti‐prelamin A | Santa Cruz SC‐6214 (amino acids 644‐664) | Goat polyclonal | 1:100 | ||||
| anti‐HDAC2 | Abcam, AB227149 | Rabbit polyclonal | 1:200 | 1:2000 | 1:200 | 5 µg | |
| anti‐HDAC2 | Santa Cruz, SC‐55541 | Mouse monoclonal | 1:200 | 1:200 | |||
| anti‐phopsho‐HDAC2 S394 | Abcam, AB75602 | Rabbit polyclonal | 1:50 | 1:50 | |||
| antiprogerin | Enzo 13A4 | Mouse monoclonal | 1:50 | 1:100 | 1:10 | ||
| anti‐p16ink4 | Santa Cruz sc‐468 | Rabbit polyclonal | 1:100 | ||||
| anti‐H4K16 acetylated | Abcam, ab109463 | Rabbit polyclonal | 1:200 | 1:4,000 | 1:200 | ||
| ant‐H4K20 acetylated | Upstate 07463 | Rabbit polyclonal | 1:200 | 1:200 | |||
| anti‐H3K9 acetylated | Millipore, 06942 | Rabbit polyclonal | 1:200 | 1:500 | 1:200 | ||
| anti‐H3 | Santa Cruz | Goat polyclonal | 1:500 | ||||
| anti‐p21 | Invitrogen, MA5‐14949 | Rabbit polyclonal | 1:100 | 1:1,000 | |||
| anti‐Flag tag | Sigma | Mouse monoclonal | 1:300 | 1:3,000 | 1 µg | ||
| anti‐GFP tag | Santa Cruz | Rabbit polyclonal | 1:500 | 3 µg | |||
| anti‐GAPDH | Millipore | Mouse monoclonal | 1:10,000 | ||||
| anti−53BP1 | Cell signaling 4937S | Rabbit polyclonal | 1:50 | ||||
| anti‐p53 | Santa Cruz sc‐126 | Mouse monoclonal | 1:500 | ||||
| anti‐p53‐S15 | Cell signaling sc‐9284 | Rabbit polyclonal | 1:500 | ||||
| anti‐NF‐YA | Santa Cruz | Rabbit polyclonal | 4 µg | ||||
| anti‐MEF2C | Cell signaling sc‐9792 | Rabbit polyclonal | 1:200 |
ChIP: chromatin immunoprecipitation assay; IF: immunofluorescence; IP: immunoprecipitation: PLA: proximity ligation assay; WB: western blot analysis.